News | November 12, 2008

Frost & Sullivan Recognizes Boston Scientific with Stent Market Leadership Award

November 13, 2008 - Based on its recent analysis of the drug eluting-stents (DES) market, Frost & Sullivan today recognized Boston Scientific with the 2008 North American Frost & Sullivan Market Leadership Award, highlighting important milestones for Boston Scientific, including FDA approvals for the PROMUS Everolimus-Eluting Coronary Stent System, the TAXUS Express2, Atom Stent, and the company's second-generation TAXUS Liberte Stent.

These product approvals enable Boston Scientific to deliver the industry's only two-drug stent portfolio as well as the largest size matrix available and reflect on Boston Scientific's commitment to delivering to patients the widest array of solutions in treating coronary artery disease.

The TAXUS Express2 Atom Paclitaxel-Eluting Coronary Stent System is one example of Boston Scientific working to expand treatment options to benefit patients, Frost & Sullivan said. The TAXUS Atom was approved by the FDA Sept. 25, making it the first DES approved for the treatment of small coronary vessels. Currently, clinicians are resigned to using either bare-metal stents, which pose a risk of restenosis, or a partially expanded DES. The TAXUS Express2 Atom, offers clinicians a more targeted solution that fulfills the size requirements of that anatomy, while reducing the risk of restenosis. That same day the FDA also announced the approval of the TAXUS Express2 for the treatment of in-stent restenosis in bare-metal stents. Both approvals expand indications for use for physicians and expand treatment options for patients.

"Although only introduced in 2003, drug eluting stents have reshaped the entire cardiovascular industry in just a few short years," says Frost & Sullivan Research Analyst Archana Swathy. "These devices are taking percutaneous coronary intervention to new heights, addressing many of the concerns and issues restricting the availability of care in the past."

Data surrounding potential safety risks associated with DES and possible late stent thrombosis had resulted in lower usage in late 2006-07. Recognizing the importance of clinical data, Boston Scientific addressed the need of physicians for additional DES safety information and continues to provide effective data that reinforce its leadership position in the DES arena, Frost & Sullivan said. Earlier this year, Boston Scientific reported encouraging one-year data from the SYNTAX trial that compared percutaneous coronary intervention (PCI) using the TAXUS Express2 paclitaxel-eluting coronary stent system to contemporary coronary artery bypass graft surgery (CABG). The TAXUS stent systems have been evaluated by the industry's most extensive randomized, controlled clinical trial program, supplemented by data on more than 35,000 patients enrolled in post-approval registries. To date, approximately 4.6 million TAXUS stents have been implanted globally, making them the world's most frequently used drug-eluting stents.

In addition to its intense focus on evidence-based medicine and a robust clinical trial program, Boston Scientific has introduced the Stentplus program to enhance patient outcomes post PCI by improving patient compliance with physician-prescribed, dual anti-platelet therapy. This comprehensive program specifically targets DES patients, regardless of the stent brand. It is endorsed by several prominent organizations, including the Society for Cardiovascular Angiography and Interventions (SCAI), and is used by nearly 1,000 hospitals and more than 160,000 patients nationwide.

Each year, Frost & Sullivan presents this award to the company that has demonstrated market share leadership through the implementation of sound market strategy. The recipient has displayed excellence in all areas of the market leadership process including the identification of market challenges, drivers, and restraints, as well as strategy development and methods of addressing these market dynamics.

Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

For more information:,

Related Content

The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent. #TCT2018

The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent.

News | Stents | October 04, 2018
October 4, 2018 – Investigators unveiled clinical data from the independent BIONYX and SORT OUT IX all-comers trials
FDA Approves Biotronik's PK Papyrus Stent for Coronary Perforations
Technology | Stents | September 27, 2018
September 27, 2018 — Biotronik recently announced U.S.
Videos | Stents | September 11, 2018
This is an animation showing how the dedicated bifurcation stent developed by Advanced Bifurcation Systems (ABS) is d
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents | January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init